Business
    Next Score View the next score

    MASS. MOVERS

    Ariad rises again, despite setback on drug

    THE BOSTON GLOBE/FILE 2011
    Ariad focuses on developing anticancer medicines.

    Shares of Ariad Pharmaceuticals Inc. climbed again Thursday, despite this week’s vote against the Cambridge company’s first cancer-fighting drug by a Food and Drug Administration panel. It recommended against FDA approval for Ridaforolimus, a treatment for metastatic soft-tissue sarcoma and bone sarcoma. But investors are apparently more excited about a third-quarter application for Ponatinib, for chronic myeloid leukemia. Analysts said Ponatinib, which could generate annual sales of $1 billion, drives the stock than Ridaforolimus.

    Advertisement